Logo

BG Medicine to Find Biomarkers, Study Drug Effects in Deal with Boehringer Ingelheim

Jul 28, 2005

NEW YORK, July 28 (GenomeWeb News) - Using its systems pharmacology platform, BG Medicine will examine the effects of drugs in tissue and discover plasma biomarkers in an agreement with Boehringer Ingelheim Pharmaceuticals, the companies said today in a statement.

 

The companies declined to disclose financial details.

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.